<DOC>
	<DOCNO>NCT00523042</DOCNO>
	<brief_summary>This trial conduct Europe , Asia , Oceania United States America ( USA ) . This one-year clinical trial compare safety inhale preprandial human insulin subcutaneous insulin aspart subject type 1 2 diabetes asthma .</brief_summary>
	<brief_title>Safety Inhaled Preprandial Human Insulin Subjects With Diabetes Asthma</brief_title>
	<detailed_description>The decision discontinue development AERxÂ® due safety concern . An analysis conclude fast-acting inhaled insulin form know today , unlikely offer significant clinical convenience benefit injection modern insulin pen device .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 1 type 2 diabetes Treatment insulin and/or oral antidiabetic drug Asthma least 6 month Positive airway reversibility/bronchoprovocation test document positive test last 3 year HbA1C less equal 11.0 % Body Mass Index ( BMI ) less equal 40.0 kg/m2 Current smoking smoking within last 6 month Other current acute chronic pulmonary disease exclude asthma Recurrent severe hypoglycaemia Proliferative retinopathy maculopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>